AI Drug Discovery Is Moving Into the Clinic — Numbers Still Have to Be Checked Case by Case
Insilico, Recursion and XtalPi are putting model-found molecules into human trials; indication, phase and response rates have to come from each company's own disclosures.
AI pharma is moving from posters into the clinic: Insilico Medicine, Recursion, Exscientia and XtalPi all have public pipelines that put model-found molecules into human trials. Whether a target was “discovered entirely by AI,” and whether a given cancer drug is already in Phase 3, has to match a company filing and a trial ID. This site will not invent a drug name, phase or response rate.
What is solid is the direction: more pipelines, shorter discovery loops. Figures such as “18 months versus 5–7 years,” “48% objective response” or “timelines cut 60% by 2030” lack a first-hand source here and should not be written as industry fact. Anyone citing a specific asset should go back to the trial registry and the company’s own disclosure.
This is an original analysis by the AI Tools Daily editorial team, based on publicly available information. Opinions are for reference only.
AI Tools Daily is a bilingual newsroom covering AI tool launches, product updates and industry trends. Editorial standards · Report a correction